Atara Biotherapeutics 향후 성장

Future 기준 점검 5/6

Atara Biotherapeutics은 연간 수입과 매출이 각각 51.1%와 32.7% 증가할 것으로 예상되고 EPS는 연간 51.5%만큼 증가할 것으로 예상됩니다.

핵심 정보

51.1%

이익 성장률

51.54%

EPS 성장률

Biotechs 이익 성장	25.4%
매출 성장률	32.7%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	18 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Feb 16

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Atara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong...

Seeking Alpha • Nov 30

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Summary Atara Biotherapeutics is on the precipice of being behind an FDA approval for a novel cell therapy. However, they do not hold the rights for this cell therapy's commercialization. Furthermore, ATRA has suspended development of their pipeline, meaning there are few, if any, catalysts to justify buying in. Read the full article on Seeking Alpha

분석 기사 • Oct 09

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 30% gain in the last...

분석 기사 • Aug 13

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...

분석 기사 • May 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...

분석 기사 • May 01

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

분석 기사 • Mar 07

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Unfortunately for some shareholders, the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price has dived 27% in the...

Seeking Alpha • Jan 21

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Summary Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on cash runway, considering delay in milestone payments related to approval as well as future royalties. Nevertheless, ATRA remains eligible for these future payments. This forced ATRA to suspend its CAR-T pipeline in search for strategic alternatives. On the bright side, this creates another short-term catalyst and allows ATRA to focus resources on EBVALLO. ATRA estimates that available cash along a newly announced $15M equity line of credit are sufficient to fund operations through approval, but the risk of further cash raise is real. Read the full article on Seeking Alpha

분석 기사 • Jan 16

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...

분석 기사 • Jan 07

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders have had their patience rewarded with a 34% share price jump...

분석 기사 • Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Those holding Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares would be relieved that the share price has rebounded...

분석 기사 • Jul 21

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...

Seeking Alpha • Jul 03

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Summary Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. Assuming no regulatory delays ATRA is well-funded to deliver proof-of-concept clinical data for its CAR-T platform in both B-cell malignancies and lupus, with an estimated cash runway into 2027. Despite fierce competition, ATRA's differentiated CAR-T platform combines all the best attributes of the competition, thus having a best-in-class potential. The major short-term risk is regulatory delays, meaning delays in pending regulatory milestone payments, which would likely necessitate a cash raise. Read the full article on Seeking Alpha

분석 기사 • May 14

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Shareholders in Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) may be thrilled to learn that the analysts have just...

분석 기사 • May 11

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

To the annoyance of some shareholders, Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares are down a considerable 26...

Seeking Alpha • Feb 06

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Summary Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NasdaqGS:ATRA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	42	9	N/A	4	4
12/31/2027	51	21	N/A	16	4
12/31/2026	1	-16	N/A	-12	2
3/31/2026	23	-9	-26	-26	N/A
12/31/2025	121	33	-51	-51	N/A
9/30/2025	152	23	-70	-70	N/A
6/30/2025	189	6	-64	-64	N/A
3/31/2025	200	-16	-67	-67	N/A
12/31/2024	129	-85	-69	-69	N/A
9/30/2024	100	-133	-95	-95	N/A
6/30/2024	62	-181	-142	-142	N/A
3/31/2024	35	-233	-185	-184	N/A
12/31/2023	9	-276	-194	-193	N/A
9/30/2023	5	-290	-201	-199	N/A
6/30/2023	7	-305	-214	-213	N/A
3/31/2023	57	-215	-226	-224	N/A
12/31/2022	64	-228	-275	-270	N/A
9/30/2022	71	-247	-254	-248	N/A
6/30/2022	72	-248	-252	-242	N/A
3/31/2022	24	-350	-250	-239	N/A
12/31/2021	20	-340	-231	-221	N/A
9/30/2021	13	-328	-199	-190	N/A
6/30/2021	7	-318	-190	-184	N/A
3/31/2021	4	-311	-185	-179	N/A
12/31/2020	N/A	-307	-185	-181	N/A
9/30/2020	N/A	-304	-242	-235	N/A
6/30/2020	N/A	-301	-242	-235	N/A
3/31/2020	N/A	-298	-239	-232	N/A
12/31/2019	N/A	-291	N/A	-236	N/A
9/30/2019	N/A	-292	N/A	-234	N/A
6/30/2019	N/A	-279	N/A	-230	N/A
3/31/2019	N/A	-256	N/A	-215	N/A
12/31/2018	N/A	-231	N/A	-180	N/A
9/30/2018	N/A	-186	N/A	-147	N/A
6/30/2018	N/A	-159	N/A	-119	N/A
3/31/2018	N/A	-135	N/A	-100	N/A
12/31/2017	N/A	-119	N/A	-88	N/A
9/30/2017	N/A	-102	N/A	-84	N/A
6/30/2017	N/A	-97	N/A	-79	N/A
3/31/2017	N/A	-88	N/A	-70	N/A
12/31/2016	N/A	-79	N/A	-60	N/A
9/30/2016	N/A	-82	N/A	-50	N/A
6/30/2016	N/A	-69	N/A	-48	N/A
3/31/2016	N/A	-65	N/A	-43	N/A
12/31/2015	N/A	-57	N/A	-37	N/A
9/30/2015	N/A	-46	N/A	-31	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ATRA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ATRA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ATRA 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ATRA 의 수익(연간 32.7%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: ATRA 의 수익(연간 32.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ATRA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/21 12:19
종가	2026/05/21 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Atara Biotherapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Michael King	Citizens JMP Securities, LLC

Atara Biotherapeutics 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates increase by 15%

Price target decreased by 32% to US$8.67

Consensus EPS estimates increase by 71%

Price target increased by 11% to US$17.00

Forecast to breakeven in 2025

Price target increased by 16% to US$15.33

Recent updates

President notifies of intention to sell stock

New major risk - Financial position

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics Provides Update on Tabelecleucel Regulatory Pathway

Atara Biotherapeutics, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 09, 2026

Pomerantz Law Firm Announces Filing Of Class Action Against Atara Biotherapeutics Inc. And Certain Officers

New major risk - Shareholder dilution

Full year 2025 earnings: EPS misses analyst expectations

Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel

Investor sentiment improves as stock rises 36%

Atara Biotherapeutics, Inc. Announces Pierre Fabre Pharmaceuticals Submits A Request to the FDA for Type A Meeting

Consensus EPS estimates increase by 15%

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Price target decreased by 32% to US$8.67

Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallo™ (Tabelecleucel)

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Atara Biotherapeutics, Inc. Announces Reduction in Its Workforce

Investor sentiment deteriorates as stock falls 19%

Pierre Fabre Pharmaceuticals Inc. Announces Transfer from Atara Biotherapeutics Inc. of the Biologics License Application (Bla) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Investor sentiment improves as stock rises 23%

Atara Biotherapeutics Announces Changes to Its Board of Directors

Consensus EPS estimates increase by 71%

Investor sentiment improves as stock rises 19%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Price target increased by 11% to US$17.00

Atara Biotherapeutics, Inc. Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®?) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New minor risk - Share price stability

New major risk - Shareholder dilution

Pierre Fabre Pharmaceuticals Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc

Atara Biotherapeutics, Inc. Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New minor risk - Insider selling

Atara Biotherapeutics, Inc. Appoints James Huang and Nachi Subramanian to Board of Directors, Effective from May 14, 2025

Forecast to breakeven in 2025

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $16.004932 million.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO™? (Tabelecleucel)

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Price target increased by 16% to US$15.33

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2025

Consensus revenue estimates decrease by 96%, EPS upgraded

Price target decreased by 7.5% to US$12.25

No longer forecast to breakeven

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Consensus EPS estimates fall by 365%

Atara Biotherapeutics, Inc. Provides Update on Clinical Programs Related to Ebvallo™? (Tabelecleucel) and ATA3219

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

New major risk - Share price stability

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

New major risk - Shareholder dilution

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2027

New minor risk - Profitability

Consensus revenue estimates increase by 14%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024